ImmunOncia, a company developing immuno-oncology drugs, recorded a competition rate of 913.24 to 1 in its public subscription for general investors as part of its IPO process.
According to Korea Investment & Securities, the IPO lead manager, ImmunOncia held its general public offering subscription over two days, concluding on May 8, 2025. The total number of shares subscribed for was 2,086,857,460, with 169,191 subscription applications submitted. The deposit, which required investors to pay half of the subscription amount in advance as collateral, amounted to approximately 3.7563 trillion KRW.
Previously, ImmunOncia had also seen strong demand during its book-building process for institutional investors held from April 22 to April 28, 2025. At that time, the competition rate was 897 to 1, and more than 97% of participating institutions bid above the upper end of the offering price range, which was 3,600 KRW. As a result, the final offering price was set at 3,600 KRW.
ImmunOncia is scheduled to be listed on the KOSDAQ market on May 19, 2025.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
